ONL Therapeutics will begin a first-in-human study of its Fas inhibitor for retinal diseases following the completion of $3 million in convertible note financing, according to a press release.
ONL1204, a first-in-class small molecule Fas inhibitor, is designed to protect key retinal cells, including photoreceptors, from cell death that occurs in many retinal diseases and conditions and leads to vision loss.
ONL is preparing ONL1204 for a phase 1 study in Australia for the treatment of retinal detachment.
The company’s management, current investors and new investors participated in the
Uncategorized